Background: Bronchial epithelial barrier leakiness and type 2 innate lymphoid cells (ILC2s) have been separately linked to asthma pathogenesis; however, the influence of ILC2s on the bronchial epithelial barrier has not been investigated previously. Objective: We investigated the role of ILC2s in the regulation of bronchial epithelial tight junctions (TJs) and barrier function both in bronchial epithelial cells of asthmatic patients and healthy subjects and general innate lymphoid cell-and ILC2-deficient mice. Methods: Cocultures of human ILC2s and bronchial epithelial cells were used to determine transepithelial electrical resistance, paracellular flux, and TJ mRNA and protein expressions. The effect of ILC2s on TJs was examined by using a murine model of IL-33-induced airway inflammation in wild-type, recombination-activating gene 2 (Rag2) and Rora sg/sg mice undergoing bone marrow transplantation that lack ILC2s did not show any barrier leakiness. Direct nasal administration of IL-13 was sufficient to induce deficiency in the TJ barrier in the bronchial epithelium of mice in vivo. Conclusion: These data highlight an essential mechanism in asthma pathogenesis by demonstrating that ILC2s are responsible for bronchial epithelial TJ barrier leakiness through IL-13. (J Allergy Clin Immunol 2018;141:300-10.)
Key words: Innate lymphoid cell, tight junction, bronchial epithelium, barrier, IL-13 Type 2 innate lymphoid cells (ILC2s) contribute to lung inflammation and asthma development. 1, 2 They produce large amounts of IL-5 and IL-13 in response to alarmins, such as IL-25 and IL-33, thereby leading to eosinophilia and goblet cell hyperplasia at bronchial surfaces, both of which are critical for asthma pathogenesis. 3, 4 Moreover, ILC2s facilitate IgE and Tcell responses to local T H 2-inducing allergens and mediate T H 2 cell differentiation through dendritic cells. 1 Their proximity to epithelial barriers and enrichment at these barriers enable ILC2s to respond rapidly to allergens on bronchial surfaces. 5 Disruption of the epithelial barrier and responses to allergens or environmental pollutants are important early events in asthma development. 6 Together with previous reports on mice and human subjects, 7, 8 these results provide evidence for the possible redundancy of the immunologic function of ILCs in the presence of the adaptive immune system. The interplay between ILC2s and T H 2 cells, which share key transcription factors and effector cytokines, is also a matter of great interest. 9 ILCs can interact with CD4 1 T cells through major histocompatibility complex II molecules, which might limit the pathologic responses of cells involved in adaptive immunity. 10, 11 The first observations of differences in tight junction (TJ) structures in asthmatic patients were made with electron microscopy in 1988, showing that varying degrees of TJ abnormalities were observed in the bronchial epithelium of healthy subjects, patients with bronchitis, and asthmatic patients. 12 Recent studies have shown that barrier function of the epithelium is impaired in patients with various inflammatory diseases, including asthma, atopic dermatitis, and chronic rhinosinusitis, and is becoming one of the most important pathogenetic features of these diseases. [13] [14] [15] [16] [17] [18] The airway epithelium forms a strong physical barrier against inhaled substances and pathogens. Part of this barrier is the mucociliary clearance, including mucus production and the ciliary transport out of the lung by epithelial cells. In addition, epithelial cells secrete antimicrobial peptides, protecting the physical barrier from pathogens. The most important function of the physical barrier formed by TJs is that it seals off paracellular spaces between neighboring epithelial cells. TJs establish the barrier at the apical side of adjacent epithelial cells of the bronchial wall and are responsible for the paracellular transport of ions and certain molecules, thereby regulating barrier integrity. 19, 20 Increased leakiness of the epithelial barrier might allow for higher penetration of allergens, microbes and their products, and pollutants across the epithelium, thus resulting in activation of the immune system, development of allergies, and exacerbations. 21, 22 Although TJs are responsible for sealing the epithelial barrier and act as the first line of defense against pathogens, regulation of barrier integrity by ILC2s was not known. In addition, it has been reported that T H 2 cytokines, such as IL-4 and IL-13, induced impaired barrier function in normal human bronchial epithelial cells (HBECs) accompanied by reduced expression of apical junctional complexes and zona occludens (ZO) 1. 23, 24 Therefore understanding the potential role of ILC2s in the breakdown of bronchial epithelial TJ barrier integrity might allow development of novel treatments targeting ILC2s in asthmatic patients. , and Rora sg/sg mice undergoing bone marrow transplantation (BMT mice) were maintained in a pathogen-free environment at the Animal Resource Centre, British Columbia Cancer Research Centre, Vancouver, Canada, and the National Research Institute for Child Health and Development, Tokyo, Japan. Female mice were used at approximately 8 to 10 weeks of age and were age matched. All animal experiments and handling procedures were approved by these institutes and performed in accordance with institutional guidelines.
RNA isolation, RNA sequencing, and data analysis Total RNA was prepared from whole murine lung tissue by using the RNeasy Mini Kit (Qiagen, Hilden, Germany). The quantity and quality of the isolated RNA was determined with a Qubit (1.0) Fluorometer (Life Technologies, Pleasanton, Calif) and a Bioanalyzer 2100 (Agilent, Waldbronn, Germany), and samples with an RNA integrity number of greater than 7.0 were chosen for sequencing. Library preparation for RNA sequencing was performed with the TruSeq Stranded mRNA Sample Prep Kit (Illumina, San Diego, Calif). For further details, see the Methods section in this article's Online Repository at www.jacionline.org.
Quantitative PCR analysis
Quantitative PCR was performed with target gene-specific primers (Microsynth, Balgach, Switzerland) and SYBR green PCR master mix (Thermo Fisher Scientific, Waltham, Mass) on an ABI PRISM 7000 Sequence Detection System (Applied Biosystems, Foster City, Calif), as described in the manufacturer's protocol. For further details, see the Methods section in this article's Online Repository.
Immunofluorescence staining of TJs
Murine lungs were directly frozen in Tissue-Tek O.C.T. Compound (Sakura Fintek, Alphen aan den rijn, The Netherlands). Sections were cut on a cryomicrotome (Carl Zeiss, Feldbach, Switzerland) at 2208C. Cryosections and air-liquid interface (ALI)-cultured cells were fixed with 4% paraformaldehyde (Sigma-Aldrich, St Louis, Mo) and permeabilized with PBS containing 0.1% Triton-X (Acros Organics, Gell, Belgium) and 0.02% SDS (SigmaAldrich). After rinsing these specimens with PBS, they were incubated with optimally diluted polyclonal rabbit anti-ZO-1 (Invitrogen, Carlsbad, Calif) at room temperature for 45 minutes and an Alexa Flour 546-labeled goat anti-rabbit antibody (Invitrogen) and Alexa Flour 488-labeled anti-occludin mAb (Invitrogen) under the same conditions for another 45 minutes. For further details, see the Methods section in this article's Online Repository.
Normal HBEC culture
Normal HBECs were purchased from Lonza (Basel, Switzerland). Cells were cultured as a monolayer in bronchial epithelial cell basal medium supplemented with the Single Quot BulletKit (Lonza) at 378C in a humidified atmosphere in 5% CO 2 . Medium was changed every second day. For further details, see the Methods section in this article's Online Repository.
Flow cytometric analysis and human ILC2 sorting
Human PBMCs were isolated by using density gradient centrifugation on Ficoll (Biochrom, Berlin, Germany). To sort cells by using flow cytometry, PBMCs were depleted of T cells, B cells, and monocytes by labeling with a cocktail of antibodies against CD3, CD14, and CD19 (Miltenyi Biotec, Bergisch Gladbach, Germany), followed by magnetic separation with an autoMACS Pro Separator (Miltenyi Biotec). Therefore CD3 
Statistical analysis
Data were analyzed by using the 2-tailed Mann-Whitney U test. A P value of less than .05 was considered significant.
RESULTS

Barrier disruption by ILC2s in ALI cultures of HBECs
To evaluate the regulation of epithelial cell TJs by ILC2s, we cultured HBECs with ILC2s using an ALI coculture system, whereby epithelial cells grown on a culture insert are exposed to air on the apical surface and culture medium containing ILC2s in the basolateral compartment. We isolated human ILC2s from peripheral blood of healthy subjects, which preferentially expressed the transcription factors retinoic acid-related orphan receptor (ROR) a and GATA-3, as well as high levels of T H 2 cytokines, such as IL-5 and IL-13 (see Fig E1, A and B, in this article's Online Repository at www.jacionline.org). As an indicator of barrier integrity, transepithelial electrical resistance (TER) revealed significantly lower values dose-dependently linked to the presence of ILC2s in ALI cultures of HBECs (Fig 1, A , and see Fig E2 in this article's Online Repository at www.jacionline. org). These experiments suggest that inhibition of ILC2s could have therapeutic potential in treating inflammation and asthma development.
We also measured TER in HBEC and freshly isolated ILC2 coculture by using a 96-well transwell plate to reduce ILC2 numbers. As shown in Fig E3 in this article's Online Repository at www.jacionline.org, TER in the presence of freshly purified ILC2s was significantly reduced on day 3 compared with control values. These data provide some supporting evidence that expanded ILC2s do preserve the functions of freshly isolated ILC2s.
To investigate whether ILC2s influenced epithelial permeability for large molecules, we then examined airway epithelial permeability based on the passage of fluorescein isothiocyanate (FITC)-conjugated 4-kDa dextran across the epithelial layers. Coculture of HBEC with ILC2s for 24 hours significantly increased the passage of fluorescently labeled dextran across the epithelial layers, which was further increased by IL-33 stimulation of ILC2s (Fig 1, B) . In the same experiments ILC2s induced expression of the mucins Muc5ac and Muc5b in HBECs (Fig 1, C) . Among the many known TJ molecules, occludin and ZO-1 represent 2 essential molecules. 25, 26 The immunostaining pattern of occludin and ZO-1 was markedly perturbed in the HBEC-ILC2 cocultures in parallel experiments in which TJ proteins dislocated away from the cell membrane and accumulated in cytosolic compartments with lower signal intensities compared with control cells (Fig 1, D and E) . In parallel, mRNA expression of occludin and ZO-1 was significantly downregulated by ILC2s (Fig 1, F) .
Neutralization of IL-13 restores human bronchial epithelial barrier integrity disrupted by ILC2s
ILC2s produced large amounts of T H 2 cytokines, such as IL-5 and IL-13 ( per well) applied basolaterally in the presence or absence of IL-33 (50 ng/mL), followed by TER measurements at different time points after cocultures. Significant decreases were observed in TER by ILC2s. All data are expressed relative to TER measured in control cells. B, Increased FITC-dextran permeability in ALI cultures by ILC2s. FITC-dextran was added to the apical chamber. Permeability assays were performed with FITC-dextran 72 hours after coculture. C, ILC2s upregulated expression of Muc5ac and Muc5b. Results were normalized with respect to EF1a levels and adjusted to negative control values. For Fig 1, A-C (n 5 4), representative data are shown. D, Immunofluorescence staining of occludin (red) and ZO-1 (green) in HBEC-ILC2 cocultures. Confluent HBECs were cocultured with ILC2s for 72 hours with or without IL-33 (50 ng/mL). Localization of TJ proteins was determined by means of immunofluorescence labeling and confocal microscopy. u.s., Unstimulated. E and F, Relative fluorescence signal intensity (Fig 1, E) and mRNA expression (Fig 1, F was used to expand ILC2s, and IL-5, which was directly released from ILC2s, did not directly influence barrier integrity (Fig 2, B and C, and see Figs E4 and E5 in this article's Online Repository at www.jacionline.org). Taken together, these results demonstrate an important role of ILC2s in airway epithelial barrier leakiness because of disruption and disassembly of TJs in human ALI cultures of HBECs.
ILCs are indispensable for IL-33-induced airway inflammation and mucus secretion
To investigate the direct in vivo effects of ILCs on barrier integrity, we examined TJs in the setting of IL-33-induced airway inflammation in T and B cell-deficient Rag2 2/2 mice and T cell-, B cell-, and innate lymphoid cell (ILC)-deficient Rag2
Il2rg
2/2 mice. 27,28 IL-33 is critical for induction of T H 2-mediated airway inflammation independent of adoptive immunity. 29, 30 Mice were administered IL-33 or PBS intranasally on days 0, 1, and 2 and then evaluated on day 3. The data demonstrated an essential role for ILCs in disruption of barrier integrity in parallel to development of inflammation in lungs. Wild-type (WT) and Rag2 2/2 mice had severe airway inflammation with increased eosinophil, macrophage, neutrophil, and lymphocyte counts in bronchoalveolar lavage (BAL) fluid after intranasal administration of IL-33 (Fig 3, A) . However, Rag2
mice did not show any lung inflammation (Fig 3, A) . In the same experiments the expression of IL-5 and IL-13 mRNA was significantly upregulated in WT and Rag2 2/2 mice, but not in Rag2 2/2 Il2rg 2/2 mice, whereas IL-4 did not show any change (Fig 3, B) . In parallel, IL-33 induced upregulation of mRNAs for the mucin genes Muc5ac and Gob5, which was not observed in ILC-deficient Rag2
2/2 mice (Fig 3, C) . These results indicated that intranasal administration of IL-33 induced an ILCdependent asthma-like inflammation.
We next explored whether ILCs modulate TJ expression in this model. Although a strong apical staining of occludin and ZO-1 was observed for bronchial epithelial cells in control airways, a marked reduction was noted in IL-33-exposed airways in WT and Rag2 2/2 mice but not in Rag2
Il2rg 2/2 mice (Fig 3, D) . It was observed in the same experiments that after exposure to IL-33, TJ gene expression was significantly downregulated in WT and Rag2 2/2 mice but not in Rag2 2/2 Il2rg 2/2 mice (Fig 3, E) . These results indicate that ILCs have an essential role for decreasing TJ expression by bronchial epithelial cells in vivo.
To investigate the effects of ILCs on the whole set of TJs and associated genes expressed in murine lungs, we performed RNA extraction and RNA sequencing on WT, Rag2
2/2
, and Rag2
Il2rg
2/2 murine lungs administered intranasally for 3 consecutive days with recombinant murine IL-33. Subsequent transcriptome analysis of 97 TJ genes revealed 61 (62.88%) of 97 genes encoding for TJ and related proteins showed a decrease in WT and Rag2 2/2 mice with IL-33 treatment, whereas no change was observed in Rag2
2/2 mice. This group of genes include Amot, Amotl1, Amotl2, Cgn, Cgnl1, Cdh5, Cldn3, Cldn5, Cldn8, Cldn12, Cldn15, Cldn18, Cldn23, Inadl, Jam1 (F11r), Jam2, Jam3, Marveld2, Marveld3, Mpdz, Mpp5, Mpp7, Magi1, Fig 3, A-C, E, and F, are means 6 SEMs. *P < .05 and **P < .01. Data represent a representative experiment from 2 independent experiments. In Fig 3, B-F 
org).
To test the effects of TJ gene regulation on epithelial barrier leakiness, we measured a 2 -macroglobulin and transferrin levels in BAL fluid. We hypothesized that these tissue proteins would leak from the tissues on disruption of barrier integrity. The data demonstrate that there was a significant leakage of tissue proteins toward the bronchial lumen from the inner lung tissue in WT and Rag2 2/2 mice but not in Rag2
Il2rg 2/2 mice after IL-33 treatment (Fig 3, F) .
ILC2s were critical for the bronchial barrier leakiness by downregulating TJs
To examine the direct involvement of ILC2s in induction of epithelial barrier dysfunction in IL-33-induced airway inflammation, we used ILC2-deficient mice generated by means of transplantation of Rora-deficient Staggerer (Rora sg/sg ) murine bone marrow, which lacks ILC2s, into irradiated CD45 congenic Pep3b mice. 1 Eosinophil and macrophage counts in BAL fluid were significantly increased in IL-33-exposed WT mice compared with Rora sg/sg BMT mice (Fig 4, A) . IL-5, IL-13, Muc5ac, and Gob5 gene expression was also upregulated in the lungs of WT mice compared with Rora sg/sg BMT mice without any change in IL-4 expression (Fig 4, B and C) .
Histologic analysis of lung sections showed decreased intercellular TJ staining of occludin and ZO-1 in lungs of WT mice but not in Rora sg/sg BMT mice (Fig 4, D) . In parallel to decreased staining of TJ proteins, mRNA expression of occludin and ZO-1 was significantly downregulated in WT but not Rora sg/sg BMT mice on IL-33 treatment, suggesting that ILC2s are key players of the observed barrier disruption in vivo (Fig 4, E) . As a marker of leakiness, increased a 2 -macroglobulin and transferrin passage into the bronchial lumen was observed in WT mice but not in the absence of ILC2s (Fig 4, F) .
Inhalation of IL-13 disrupted bronchial epithelial TJ barrier
The above results suggest that ILC2s are playing a major role in bronchial barrier leakiness by downregulating TJ expression. Because IL-13 was implicated as an important mediator of ILC2-induced barrier leakiness in our in vitro studies, we tested the effect of intranasally administered IL-13 on the bronchial epithelium in mice. IL-13 directly upregulated the expression of mucus-related genes, such as Muc5ac and Gob5, as observed above in the setting of IL-33-induced airway inflammation (Fig  5, A) . Mice treated with IL-13 displayed substantially lower expression of occludin and ZO-1 TJ molecules compared with control mice in the bronchial epithelial cells of the lungs (Fig 5,  B) . Gene expression analysis also revealed a slight but significantly low expression of TJ mRNAs after IL-13 treatment (Fig  5, C) . As observed in the above-described experiments, protein passage from the lung tissues toward the bronchial lumen was abundantly increased by IL-13 administration (Fig 5, D) .
DISCUSSION
The data presented here demonstrate that ILC2-derived IL-13 directly influences the bronchial TJ barrier both in human subjects and mice. Asthma is a chronic inflammatory disorder of the airways characterized by reversible obstruction. 31, 32 Type 2 inflammation, with the major role of ILC2s and T H 2 cells and their cytokines, is considered a major pathophysiologic mechanism of asthma. 33 ILCs control the mucosal environment through close interaction with epithelial cells and other tissue cells, production of cytokines, and induction of chemokines that recruit suitable cell populations to initiate and promote distinct types of immune response development and tissue inflammation. After allergen sensing, epithelial cells can produce IL-1a, IL-25, IL-33, thymic stromal lymphopoietin, and GM-CSF, which start to orchestrate type 2 immunity. 34 Within these many cytokines, IL-33 is a major cytokine that particularly activates ILC2s and represents the rationale to use IL-33-induced lung inflammation models.
Indeed, a previous study has shown that intranasal administration of ovalbumin (OVA) alone to WT mice did not induce detectable T H 2 cell differentiation, whereas coadministration of OVA plus IL-33 efficiently induced T H 2 cell differentiation through IL-33-mediated ILC2 activation. 1 This activation and T H 2 cell differentiation are both IL-33 dependent. On the other hand, house dust mite (HDM) allergens directly activate bronchial epithelial cells, particularly the breakdown of TJ barriers. 26, 35 For this reason, the HDM model does not seem to be appropriate for evaluating the effect of ILC2s on TJs. In addition, recently, it was suggested that ILC2 induction in HDM-mediated allergic airway inflammation in mice critically depends on T-cell activation. 36 Furthermore, the presence of B cells can also lead to increased lung T H 2 immunity and asthmatic characteristics of the response to HDM. 37 Thus to see the consequence of ILC2 dependency but not T H 2 cells on TJ barrier function, we used IL-33-induced airway inflammation, which is a model dependent particularly on ILC2s.
ILC2s and other ILC subsets are known to be responsible for the regulation of epithelial functions also in other organs. 38, 39 The interaction of epithelial cells with ILCs has been extensively studied in the gut mucosa. 10, [40] [41] [42] [43] For example, previous studies demonstrated that IL-22-producing ILC3s modulated epithelial glycosylation. 44 In the skin E-cadherin ligation exerted an inhibitory effect on ILC2 activation, suggesting that settings associated with low expression of E-cadherin promoted ILC2 activation. 45 Our results showing ILC2-dependent disruption of the epithelial barrier through downregulation of TJ expression might also be relevant for epithelial cells in other organs. ) BMT mice (n 5 5) administered with PBS or IL-33 for 3 consecutive days were killed on day 3, followed by quantification of inflammatory cell populations in BAL fluid (numbers of cells per milliliter) by using flow cytometry. B and C, IL-4, IL-5, and IL-13 (Fig 4, B) and Muc5ac and Gob5 (Fig 4, C) mRNA expression in lungs from WT and Rora sg/sg BMT mice measured by using quantitative PCR on day 3.
D, Occludin and ZO-1 staining in bronchial walls of WT and Rora sg/sg BMT mice after treatment with PBS or IL-33 on day 3. E, WT and Rora sg/sg BMT mice were treated with PBS or IL-33, and relative gene expression of occludin and ZO-1 was analyzed by using quantitative PCR on day 3. F, ILC2s promoted epithelial leakiness from tissues toward the mucosal lumen. a 2 -Macroglobulin and transferrin levels in BAL fluid after treatment with IL-33 on day 3 in WT and Rora sg/sg BMT mice, as measured by using ELISA. Values in Fig 4, A-C , E, and F, are means 6 SEMs. *P < .05 and **P < .01. In Fig 4, B-F , all analyses were done in triplicate.
J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 1 TJs form big complexes in the cell membrane consisting of 3 major types of transmembrane proteins: the claudin family, the TJ-associated MARVEL protein family, and single-span proteins, such as the immunoglobulin-like proteins junction adhesion molecules and Coxsackie adenovirus receptor. 46, 47 Intracellularly, transmembrane proteins bind to several scaffold proteins, such as the ZO family, and are consequently connected to the actin cytoskeleton. 48 Some of the TJ gene expressions were validated by means of quantitative PCR. It has to be noted here that these analyses do not demonstrate kinetic and linear experiments, and our mRNA sequencing experiment represents the first identification of TJ gene regulation by ILCs. In addition, in our hands next-generation mRNA sequencing transcriptomics is a highly reliable method, and the data have been always confirmed and strongly correlate with PCR in the same samples. mRNA sequencing has also been shown to be highly accurate and reliable for quantifying gene expression levels. 49 IL-13 appeared to be a key effector cytokine in ILC2-induced bronchial epithelial leakiness in the present study. Its direct TJdisruptive effects and barrier-breaking roles were demonstrated in experiments with IL-13 neutralization in ILC2 cocultures with HBECs, as well as direct intranasal IL-13 treatment of mice. IL-13 activates the same signal transduction pathways as IL-4 and induces IgE production. It also activates and recruits mast cells and eosinophils and promotes their survival. IL-13-deficient mice produce less IL-4, IL-5, IL-10, and IgE and do not experience goblet cell hyperplasia. [50] [51] [52] IL-5 and IL-13 from ILC2s play an important role in eosinophilic asthma. 53 Significantly greater numbers of sputum IL-5 1
IL-13
1 ILC2s were observed in patients with severe asthma, whose airway eosinophilia was greater than 3% despite normal blood eosinophil numbers. 54 In HBEC-ILC cocultures HBECs were seeded at a density of 150,000 cells, and at least 50,000 ILC2s influenced epithelial permeability (see Fig E2) . It was demonstrated in human subjects that the number of ILC2s in sputum is increased in patients with severe asthma. 54 This study and our in vitro dose-dependent regulation of barrier disruption by ILC2s might provide evidence that ILC2s promote the development of asthma by decreasing epithelial permeability in human subjects. Although the ILC2/HBEC ratio (1:3) was concluded in vitro, it might not fully reflect the in vivo situation and complexity of the airway inflammation. The present study demonstrates an important mechanism of action of IL-13 in the asthmatic patient in addition to the above mentioned functions. Like many chronic diseases, asthma shows remissions and exacerbations, and leakiness in the bronchial epithelial wall might be one of the main reasons for chronicity, in which ILC2s can play a major role.
In addition to ILC2s, IL-13 is expressed by T H 2 cells, mast cells, basophils, eosinophils, and natural killer T cells. Our recombinant IL-13 administration experiments do not specifically represent the source of IL-13, irrespective of whether it is T H 2 cell or ILC2 derived. The present study has focused on and demonstrated a particular role of ILC2s in IL-13-induced bronchial leakiness by experiments. 27, 28 Asthma-like eosinophilic lung inflammation was developed as long as ILCs were present in the mice, and accordingly, the WT and Rag2 2/2 mice experienced severe airway inflammation with increased eosinophil, macrophage, neutrophil, and lymphocyte counts in BAL fluid, whereas Rag2
2/2
Il2rg
2/2 mice did not show any lung inflammation. Although this model took a general approach to ILCs, a second set of experiments was conducted particularly targeting the FIG 5 . IL-13 directly disrupts the bronchial epithelial TJ barrier in vivo. A, One microgram of recombinant murine IL-13 or PBS was administered intranasally to C57BL/6J mice (n 5 6 each) on days 0, 1, and 2. Mice were killed 1 day later, and BAL fluid (1 mL PBS) and lungs were collected. On day 3, lung mRNA expression was analyzed for mucus-related genes. Both Muc5ac and Gob5 were significantly upregulated after inhalation of IL-13. B, Murine lungs were stained with Alex Fluor 488-labeled antioccludin mAb or Alexa Fluor 488-labeled anti-ZO-1. C, To look for the TJ gene expressions, we isolated mRNA from lungs on day 3. IL-13 downregulates both occludin and ZO-1 mRNA expressions. D, To analyze the direct effect of IL-13 on epithelial leakiness, we measured protein levels in BAL fluid 24 hours after final administration of IL-13. a 2 -Macroglobulin and transferrin levels in BAL fluid were significantly increased after IL-13 treatment. Values in Fig 5, A, C , and D, are means 6 SEMs. **P < .01. All analyses were done in triplicates.
role of ILC2s. The use of Rora sg/sg BMT mice in the model of IL-33-induced airway inflammation highlighted the role of ILC2s in epithelial leakiness. Again, the development of eosinophilic inflammation was hindered in ILC2-deficient mice, and lung sections showed decreased TJ staining in the lungs of WT mice but not in Rora sg/sg BMT mice, suggesting the critical role of ILC2s in barrier disruption.
The leaky barrier function of asthmatic epithelium with decreased TER and increased paracellular flux in human ALI cultures of bronchial epithelium has been reported to take place even after 2 to the 3 passages of the primary epithelial cells. 55 These findings have suggested the role of epigenetics, and an essential role of IL-13 on epigenetic regulation of asthmatic epithelium has been demonstrated recently. IL-13 is a potent upregulator of histone deacetylases (HDACs), and increased HDAC activity has been reported to cause epithelial leakiness in asthmatic patients. Thus dupilumab, an inhibitor of IL-4 and IL-13 signaling, might modulate HDAC activity and then increase lung function in asthmatic patients. 56 However, given the similarities between ILC2s and T H 2 cells with regard to transcription factor expression, cytokine secretion, and localization, 9 our in vivo ILC2-dependent murine data indicate that ILC2s have the potential to promote epithelial barrier breakdown by producing IL-13. However, according to the most recent studies showing the redundant role of ILCs, ILC2s seem to be dispensable once T cells have been activated. 7, 8 Together with our results, these findings suggest that cooperation between ILC2s and T H 2 cells is involved as a mechanism that leads to inflammatory diseases, such as asthma. In addition, ILC2s have also been reported to have an indirect effect on memory T H 2 cell recruitment. 57 In another report, mice that lack ILC2s but have T H 2 cells display reduced T H 2 cytokine and IgE levels, suggesting the importance of ILC2s in bridging innate to adaptive T H 2 responses. 58 In conclusion, the finding that ILC2s exacerbate lung inflammation through disruption of epithelial barrier homeostasis provides a novel function for ILC2s in targeting TJ expression. The role of IL-13 produced by ILC2s to induce bronchial epithelial barrier disruption represents a novel pathophysiologic mechanism and molecular target for the treatment of asthma.
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METHODS
IL-33-induced airway inflammation
Recombinant murine IL-33 (0.5 mg; PeproTech, Rocky Hill, NJ) in 20 mL of PBS was administered intranasally for 3 consecutive days. Control mice were exposed to PBS alone. BAL fluid was analyzed 24 hours after the final treatment. Cell counts in BAL fluid were determined with a Sysmex analyzer (Sysmex, Kobe, Japan) or by using flow cytometry. Lungs were removed and stored at 2808C for histologic analyses, and lung tissues were homogenized to isolate RNA.
IL-13 inhalation experiments
One microgram of recombinant murine IL-13 (eBioscience) or PBS was administered intranasally to female C57BL/6J mice on days 0, 1, and 2. Mice were killed 1 day later, and BAL fluid (1 mL PBS) was collected. The left airways were then instilled with 50:50 Tissue-Tek O.C.T. Compound (Andwin Scientific, Schaumberg, Ill), and the left lobe was collected for freezing. Right lobes were then put into 1 mL of RNAlater and frozen at 2808C.
RNA isolation, RNA sequencing, and data analysis
Total RNA samples (1 mg) were ribosome depleted and then reverse transcribed into double-stranded cDNA, with actinomycin added during first-strand synthesis. cDNA samples was fragmented, end-repaired, and polyadenylated before ligation of TruSeq adapters. The adapters contain the index for multiplexing. Fragments containing TruSeq adapters on both ends were selectively enriched with PCR. The quality and quantity of the E1,E2 Gene and isoform levels were quantified as RPKM values. Clustering analyses were performed with the ''ward.D2'' clustering algorithm implemented in the ''hclust'' function of the R statistics package. Heat map plots were performed with the function ''heatmap.2'' implemented in the gplots R package. Differential expression analysis between 2 groups was performed with the edgeR Bioconductor package. E3 Genes present in less than 75% of samples in both conditions were removed. Q values were calculated by using the Benjamini-Hochberg method, and genes with a q value of less than 0.05 and an absolute log 2 value (fold change) of greater than 1 were kept for further analysis. Gene ontology (GO) term enrichment analysis was performed with the GOseq bioconductor package by using the Wallenius approximation. In parallel, pathway analysis was performed with MetaCore (version 6.23) software (Thomson Reuters, Rochester, NY). E4 The set of TJs and related molecules was assembled from a GO database.
Measurement of a 2 -macroglobulin and transferrin levels a 2 -Macroglobulin and transferrin levels in BAL fluid samples were measured with a murine-specific a 2 -macroglobulin ELISA (Abbexa, Cambridge, United Kingdom) and murine-specific transferrin ELISA (ALPCO Diagnostics, Salem, NH) kits.
Quantitative PCR analysis
The sequences of the primers to detect target gene expression are listed below. An amount of elongation factor 1a (EF1a) mRNA was used to standardize the quantities of each transcript according to the 2 2DDCT value.
Mouse primers used were as follows: 
Immunofluorescence staining of TJs
In some experiments Alexa Flour 488-labeled anti-ZO-1 was used for staining. Slides were then mounted with ProLong-Gold Antifade Reagent (Invitrogen). Specimens were examined with a confocal microscope (Leica TCS SPE, Heerbrugg, Switzerland). Data were analyzed and fluorescent intensities were quantified with ImageJ software (National Institutes of Health, Bethesda, Md).
HBEC culture
Cells were seeded at a density of 150,000 cells in a 6.5-mm diameter polyester membrane with a pore size of 0.4 mm (Corning, Corning, New York) in medium for the ALI culture, as reported previously, E5 to develop ALI cultures. Once the cells grew to complete confluence, the apical compartment was freed of any medium to allow further differentiation by these cells. In some experiments IL-2 (Proleukin Proreo Pharma, Liestal, Switzerland) or IL-5 (all from PeproTech) was added to cultures.
Flow cytometric analysis and human ILC2 sorting
The following antibodies to human proteins were used to determine the expression of surface markers: FITC-conjugated anti-CD1a (HI149), anti-CD3 (OKT3), anti-CD4 (RPA-T4), anti-T-cell receptor TCRab (IP26), 
CD127
1 CRTH2 1 ILC2s were expanded with irradiated PBMCs (25 Gy), PHA (1 mg/mL; Sigma-Aldrich), and IL-2 (100 U/ mL) in Yssel medium supplemented with 1% (vol/vol) human AB serum, as reported previously. E6,E7 Cells were then cultured in 96-well plates at a density of 5000 cells per well. Half of the medium was replaced with fresh medium every 2 to 3 days. The irradiated cells were degraded within 1 to 2 weeks of culture. ILC2s were cultured for up to 6 weeks, and purity was confirmed by using fluorescence-activated cell sorting for further analyses. In some experiments cell cultures were treated with IL-33 (50 ng/mL; PeproTech).
HBEC-ILC2 cocultures
HBECs and ILC2s were cultured together in the presence of transwell inserts, in which HBECs and ILC2s were placed in the upper and lower compartments, respectively. In all experiments except the dose-response experiment, 50 3 10 3 ILC2s were added to the basolateral compartment. In the dose-response experiment increasing amounts of ILC2s (25, 50, and 100 3 10 3 cells) were used per well. ILC2s were simultaneously cultured separately without HBECs. In the indicated experiments IL-2 (100 U/mL) and/or IL-33 (50 ng/mL) were added to the cultures. In inhibition experiments IL-4 or IL-13 blocking mAbs (R&D Systems, Wiesbaden, Germany) were used at 10 mg/mL, according to the manufacturer's protocol. Isotype controls (R&D Systems) were used at the same concentrations.
TER and paracellular flux measurements
TER and the paracellular leakage of 4-kDa FITC-labeled dextran (SigmaAldrich) were determined as surrogate markers of barrier integrity. TER was measured at the indicated time points before and after coculture with a Millicell-ERS Volt Ohm Meter (Millipore, Temecula, Calif). Paracellular flux measurements were performed after TER experiments. Paracellular permeability was evaluated 24 hours after apical addition of 2 mg/mL FITC-dextran. The FITC intensity of the basolateral medium was assessed with an ELISA reader (Mithras LB 940; Berthold Technologies, Bad Wildbad, Germany) at 480 nm. 
Quantification of cytokines
FIG E2.
ILC2s reduced paracellular permeability in a dose-dependent manner. HBECs were incubated with the indicated ILC2s applied basolaterally, followed by TER measurements at different time points after coculture. Significant decreases were observed in TER by ILC2s in a dosedependent manner. All data are expressed relative to TER measured in control cells. All analyses were done in triplicates. **P < .01. u.s., Unstimulated. were cocultured with or without IL-33 (n 5 3). TER of HBECs was significantly reduced in freshly isolated ILC2 cocultures compared with culture without ILC2s. Values are means 6 SEMs. **P < .01. u.s., Unstimulated.
FIG E4.
Effects of IL-2 or IL-5 on ALI-cultured HBECs. HBECs were incubated with or without various cytokines, followed by TER measurements at different time points after coculture. All data are expressed relative to TER measured in control cells. IL-2 (100 U/mL; A) or IL-5 (50 ng/mL; B) treatment is shown. There are no significant differences between unstimulated (u.s.) conditions and each cytokine. All analyses were done in triplicates.
FIG E9.
Confirmation of upregulated and downregulated genes by using quantitative PCR. Relative mRNA expression levels of Marveld2, Marveld3, Cldn1, and Cldn4 in lungs after final administration of IL-33 were determined by using quantitative PCR. IL-33 downregulated gene expression of Marveld2 and Marveld3, whereas Cldn1 and Cldn4 were upregulated in WT and Rag2 2/2 mice. There was no effect in Rag2 J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 1
